Developing a new oral treatment for pulmonary arterial hypertension.
Official title: Development of a novel disease modifying oral therapy for pulmonary arterial hypertension.
Funded at Vasculonics, LLC · NIH-11006726 · Data updated 2026-11-12
This study is testing a new oral medication called VN-1032 that aims to help people with pulmonary arterial hypertension (PAH) by slowing down the disease and easing symptoms.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasculonics, LLC NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | August 23, 2019 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,077,584 |
| NIH project number | 2R44HL149496-02A1 |
| Project ID | NIH-11006726 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension who are currently experiencing disease progression despite existing therapies.
✕Less likely to help
Patients who do not have pulmonary arterial hypertension or those whose condition is stable and well-managed with current therapies may not benefit from this research.
What this research studies
This research focuses on creating a novel oral therapy, VN-1032, aimed at modifying the disease progression of pulmonary arterial hypertension (PAH). PAH is a serious condition characterized by high blood pressure in the lungs, leading to severe health complications. The approach involves targeting specific biological pathways, particularly the Aryl hydrocarbon Receptor (AhR) and asymmetric dimethylarginine (ADMA), which are known to contribute to the disease. By inhibiting these pathways, the therapy aims to not only alleviate symptoms but also slow down or halt the progression of PAH.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that modifies the course of pulmonary arterial hypertension, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While there has been significant research into PAH treatments, the specific approach targeting AhR and ADMA with VN-1032 represents a novel strategy that has not been extensively tested in clinical settings.
Where this research is happening
-
Vasculonics, LLC
Indianapolis, United States Active
Researchers
- Principal investigator: Singh, Jaipal — Vasculonics, LLC
- Study coordinator: Singh, Jaipal
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.